Immunotherapy approved for a type of rectal cancer, sometimes without surgery
Published
FDA gave accelerated approval to GSK's Jemperli for stage II or III rectal cancer with a genetic feature called MSI-H or dMMR. In the main study, most patients treated with the drug alone needed no further treatment during follow-up. If you have rectal cancer, ask whether your tumor has been tested for this feature.
Source: The ASCO Post
This is a plain-language summary. Read the original source for full details.